Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms

PURPOSE: The JAK1/2 inhibitor ruxolitinib has demonstrated significant benefits for patients with Myeloproliferative Neoplasms (MPNs). However, patients often lose response to ruxolitinib or suffer disease progression despite therapy with ruxolitinib. These observations have prompted efforts to devi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Rampal, Raajit K., Pinzon-Ortiz, Maria, Somasundara, Amritha Varshini Hanasoge, Durham, Benjamin, Koche, Richard, Spitzer, Barbara, Mowla, Shoron, Krishnan, Aishwarya, Li, Bing, An, Wenbin, Derkach, Andriy, Devlin, Sean, Rong, Xianhui, Longmire, Tyler, Eisman, Shira Esther, Cordner, Keith, Whitfield, Justin T., Vanasse, Gary, Cao, Alexander, Levine, Ross L.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8197756/
https://ncbi.nlm.nih.gov/pubmed/33782031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-4898
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky